Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group

Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group

Background: In clinical studies, first-line afatinib demonstrated efficacy in Del19-EGFR NSCLC. Materials and Methods: This prospective, non-interventional study assessed efficacy and safety of first-line afatinib in patients with advanced/metastatic NSCLC with Del19-EGFR from Galicia (Spain), with...

Full description

Bibliographic Details
Main Authors: Sara Agraso, Martin Lázaro, Xose Luis Firvida, Lucía Santomé, Natalia Fernández, Cristina Azpitarte, Luis Leon, Carme Garcia, Gerardo Hudobro, Ma Carmen Areses, Begoña Campos, Nazaret Quiroga, Jorge García, Joaquín Casal
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Real world data
Afatinib
Non-small cell lung cancer NSCLC
Epidermal growth factor receptor
EGFR positive mutation
Del 19 EGFR
Online Access:http://www.sciencedirect.com/science/article/pii/S246829422200137X

Internet

http://www.sciencedirect.com/science/article/pii/S246829422200137X

Similar Items